In Sweden, approximately 4000 patients are diagnosed with a haematological malignancy every year. Leukaemias and lymphomas are dominating.Despite a continuous improvement in treatment options many patients succumb from their disease.In addition,patients who have been cured may develop therapy related complications like secondary tumours,cardiovascular disease,reduced fertility and hormonal abnormalities
Our research endeavours ultimately to improve disease outcome by identifying risk factors for disease and identify biological tumour characteristics,with a special focus on inflammation,in these tumour entities.The results we hope can contribute to preventive measures,improved diagnostics and new principles of therapy and drugs.
The discoveries made have been possible through an interdisciplinary composition of the research group including experimental researchers in inflammation and tumour biology and specialists in diagnostics,treatment and epidemiology.In addition,the access to unique Swedish population registers is another importent success factor.
We study blood cancer in the Swedish population - familial risk factors, precancerous conditions, prognosis and treatment related complications. Findings are related to biological characteristics of the tumor forming a base for new diagnostic and treatment principles
Elucidation of the regulatory mechanism and role of telomerase, a RNA-dependent DNA polymerase, in aging and cancer.
Fluorescence in situ hybridization (FISH) for the identification of clonal malignant cells in myeloid leukemia (CML) -bioloical significiance and outcome of therapy
Characterization of inflammation and immune mechanisms in monoclonal gammopathies and foreign body reactions (insect-mammalian).